BR0115847A - Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos - Google Patents
Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmosInfo
- Publication number
- BR0115847A BR0115847A BR0115847-3A BR0115847A BR0115847A BR 0115847 A BR0115847 A BR 0115847A BR 0115847 A BR0115847 A BR 0115847A BR 0115847 A BR0115847 A BR 0115847A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- specific compounds
- adenosine receptor
- receptor specific
- patient
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 102000009346 Adenosine receptors Human genes 0.000 title abstract 3
- 108050000203 Adenosine receptors Proteins 0.000 title abstract 3
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
- 229960005305 adenosine Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/728,616 US7160890B2 (en) | 1999-12-02 | 2000-12-01 | Compounds specific to adenosine A3 receptor and uses thereof |
| US09/728,607 US6664252B2 (en) | 1999-12-02 | 2000-12-01 | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
| US09/728,316 US6680322B2 (en) | 1999-12-02 | 2000-12-01 | Compounds specific to adenosine A1 receptors and uses thereof |
| PCT/US2001/045280 WO2002057267A1 (en) | 2000-12-01 | 2001-11-30 | Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0115847A true BR0115847A (pt) | 2004-02-25 |
Family
ID=27419112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0115847-3A BR0115847A (pt) | 2000-12-01 | 2001-11-30 | Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1347980A4 (cs) |
| JP (1) | JP4579497B2 (cs) |
| CN (1) | CN1263757C (cs) |
| AP (1) | AP1893A (cs) |
| AU (1) | AU2002248151B2 (cs) |
| BR (1) | BR0115847A (cs) |
| CA (1) | CA2430577A1 (cs) |
| CZ (1) | CZ20031831A3 (cs) |
| EA (1) | EA007254B1 (cs) |
| HU (1) | HUP0400692A3 (cs) |
| IL (1) | IL155962A0 (cs) |
| ME (1) | MEP35308A (cs) |
| MX (1) | MXPA03004717A (cs) |
| NO (1) | NO327207B1 (cs) |
| NZ (1) | NZ525885A (cs) |
| OA (1) | OA13295A (cs) |
| PL (1) | PL363245A1 (cs) |
| WO (1) | WO2002057267A1 (cs) |
| YU (1) | YU42703A (cs) |
| ZA (1) | ZA200303729B (cs) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5090531A (en) * | 1990-01-10 | 1992-02-25 | Lord Corporation | Electrophoretic fluid differential |
| ID27600A (id) | 1998-06-02 | 2001-04-12 | Osi Pharm Inc | KOMPOSISI PIROLO (2,3d) PIRIMIDIN DAN PENGGUNAANNYA |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| DE10148883A1 (de) | 2001-10-04 | 2003-04-10 | Merck Patent Gmbh | Pyrimidinderivate |
| DK1450811T3 (da) | 2001-11-30 | 2010-02-15 | Osi Pharm Inc | Forbindelser specifikke af adenosin A1- og A3-receptorer og anvendelser heraf |
| DE60236322D1 (de) * | 2001-12-07 | 2010-06-17 | Vertex Pharma | Verbindungen auf pyrimidin-basis als gsk-3-hemmer |
| US20030229067A1 (en) | 2001-12-20 | 2003-12-11 | Arlindo Castelhano | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use |
| DE60235500D1 (de) | 2001-12-20 | 2010-04-08 | Osi Pharm Inc | Selektive pyrimidin-a2b-antagonistenverbindungen, ihre synthese und verwendung |
| US7199119B2 (en) * | 2002-10-31 | 2007-04-03 | Amgen Inc. | Antiinflammation agents |
| HUP0203976A3 (en) * | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| DE602006013792D1 (de) * | 2005-02-18 | 2010-06-02 | Solvay Pharm Gmbh | Pharmazeutische zusammensetzungen mit nep-inhibitoren, inhibitoren des endogenes endothelin produzierenden systems und diuretika |
| EP3719018B1 (en) | 2006-04-25 | 2025-08-27 | Astex Therapeutics Ltd | Purine and deazapurine derivatives as pharmaceutical compounds |
| US20070260203A1 (en) * | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
| TW200808819A (en) * | 2006-06-19 | 2008-02-16 | Solvay Pharm Gmbh | Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty |
| BRPI0818533B8 (pt) | 2007-10-11 | 2021-05-25 | Astrazeneca Ab | composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto |
| AR070127A1 (es) | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
| JP2011509290A (ja) | 2008-01-11 | 2011-03-24 | ナトコ ファーマ リミテッド | 抗癌剤としてのピラゾロ［３，４‐ｄ］ピリミジン誘導体 |
| SG193505A1 (en) | 2011-04-01 | 2013-10-30 | Astrazeneca Ab | Therapeutic treatment |
| PH12014500943A1 (en) | 2011-11-30 | 2014-06-30 | Astrazeneca Ab | Combination treatment of cancer |
| AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
| CA2873723A1 (en) * | 2012-06-07 | 2013-12-12 | F. Hoffmann-La Roche Ag | Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase |
| HRP20200854T1 (hr) | 2013-06-21 | 2020-08-21 | Zenith Epigenetics Ltd. | Novi biciklički inhibitori bromodomene |
| WO2015004534A2 (en) * | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| EA201690087A1 (ru) | 2013-07-31 | 2016-08-31 | Зенит Эпидженетикс Корп. | Новые квиназолиноны как ингибиторы бромодомена |
| US10710992B2 (en) | 2014-12-01 | 2020-07-14 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| US10179125B2 (en) | 2014-12-01 | 2019-01-15 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
| WO2016092375A1 (en) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Corp. | Substituted heterocycles as bromodomain inhibitors |
| WO2016097863A1 (en) | 2014-12-17 | 2016-06-23 | Zenith Epigenetics Corp. | Inhibitors of bromodomains |
| EP3248980B1 (en) * | 2015-01-20 | 2023-09-06 | Wuxi Fortune Pharmaceutical Co., Ltd | Jak inhibitor |
| EP3290418B1 (en) | 2015-04-29 | 2019-05-15 | Wuxi Fortune Pharmaceutical Co., Ltd | Janus kinase (jak) inhibitors |
| UA118822C2 (uk) | 2015-05-29 | 2019-03-11 | Вуксі Фортуне Фармасьютікал Ко., Лтд | Інгібітор янус-кінази |
| CN105771672B (zh) * | 2016-04-18 | 2018-03-02 | 天津工业大学 | 一种抗污染抗菌芳香聚酰胺反渗透复合膜及制备方法 |
| CN108570054B (zh) * | 2017-03-07 | 2021-07-16 | 广州再极医药科技有限公司 | 氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用 |
| CN108017584B (zh) * | 2017-06-20 | 2021-03-23 | 南开大学 | A3腺苷受体的小分子拮抗剂 |
| US11786528B2 (en) * | 2018-06-04 | 2023-10-17 | Exscientia Ltd. | Pyrazolopyrimidine compounds as adenosine receptor antagonists |
| CN110128316B (zh) * | 2019-05-22 | 2021-08-31 | 北京大学深圳研究生院 | 5位取代的β-脯氨酸及其衍生物的制备方法 |
| CN110272373B (zh) * | 2019-07-02 | 2022-07-29 | 天津国际生物医药联合研究院 | 一种具有选择性的腺苷a1受体拮抗剂及其应用 |
| CN114085178A (zh) * | 2021-12-29 | 2022-02-25 | 苏州楚凯药业有限公司 | 一种4-甲基-1-丙基-2-氨基-1h-吡咯-3-腈的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9307646A (pt) * | 1992-12-17 | 1999-05-25 | Pfizer | Pirrolopirimidinas como antagonistas de crf |
| US5780450A (en) * | 1995-11-21 | 1998-07-14 | Alcon Laboratories, Inc. | Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage |
| ID27600A (id) * | 1998-06-02 | 2001-04-12 | Osi Pharm Inc | KOMPOSISI PIROLO (2,3d) PIRIMIDIN DAN PENGGUNAANNYA |
| WO2001039777A1 (en) * | 1999-12-02 | 2001-06-07 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof |
| DK1450811T3 (da) * | 2001-11-30 | 2010-02-15 | Osi Pharm Inc | Forbindelser specifikke af adenosin A1- og A3-receptorer og anvendelser heraf |
-
2001
- 2001-11-30 AP APAP/P/2003/002807A patent/AP1893A/en active
- 2001-11-30 BR BR0115847-3A patent/BR0115847A/pt not_active Application Discontinuation
- 2001-11-30 PL PL01363245A patent/PL363245A1/xx not_active Application Discontinuation
- 2001-11-30 AU AU2002248151A patent/AU2002248151B2/en not_active Ceased
- 2001-11-30 YU YU42703A patent/YU42703A/sh unknown
- 2001-11-30 CA CA002430577A patent/CA2430577A1/en not_active Abandoned
- 2001-11-30 ME MEP-353/08A patent/MEP35308A/xx unknown
- 2001-11-30 WO PCT/US2001/045280 patent/WO2002057267A1/en active IP Right Grant
- 2001-11-30 OA OA1200300148A patent/OA13295A/en unknown
- 2001-11-30 CZ CZ20031831A patent/CZ20031831A3/cs unknown
- 2001-11-30 NZ NZ525885A patent/NZ525885A/en active IP Right Revival
- 2001-11-30 IL IL15596201A patent/IL155962A0/xx unknown
- 2001-11-30 EP EP01997029A patent/EP1347980A4/en not_active Ceased
- 2001-11-30 EA EA200300628A patent/EA007254B1/ru not_active IP Right Cessation
- 2001-11-30 JP JP2002557944A patent/JP4579497B2/ja not_active Expired - Fee Related
- 2001-11-30 CN CNB018224601A patent/CN1263757C/zh not_active Expired - Fee Related
- 2001-11-30 MX MXPA03004717A patent/MXPA03004717A/es active IP Right Grant
- 2001-11-30 HU HU0400692A patent/HUP0400692A3/hu unknown
-
2003
- 2003-05-14 ZA ZA200303729A patent/ZA200303729B/en unknown
- 2003-06-02 NO NO20032482A patent/NO327207B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002248151B2 (en) | 2008-02-21 |
| MEP35308A (en) | 2011-02-10 |
| CN1263757C (zh) | 2006-07-12 |
| EP1347980A1 (en) | 2003-10-01 |
| NO20032482L (no) | 2003-07-28 |
| HUP0400692A2 (hu) | 2004-07-28 |
| EP1347980A4 (en) | 2005-02-09 |
| ZA200303729B (en) | 2004-05-14 |
| HUP0400692A3 (en) | 2007-09-28 |
| OA13295A (en) | 2007-04-13 |
| NZ525885A (en) | 2005-01-28 |
| MXPA03004717A (es) | 2004-06-30 |
| WO2002057267A1 (en) | 2002-07-25 |
| PL363245A1 (en) | 2004-11-15 |
| JP2004517896A (ja) | 2004-06-17 |
| CZ20031831A3 (cs) | 2004-05-12 |
| YU42703A (sh) | 2006-03-03 |
| CN1489590A (zh) | 2004-04-14 |
| NO20032482D0 (no) | 2003-06-02 |
| AP1893A (en) | 2008-09-23 |
| EA007254B1 (ru) | 2006-08-25 |
| CA2430577A1 (en) | 2002-07-25 |
| NO327207B1 (no) | 2009-05-11 |
| IL155962A0 (en) | 2003-12-23 |
| JP4579497B2 (ja) | 2010-11-10 |
| EA200300628A1 (ru) | 2003-12-25 |
| AP2003002807A0 (en) | 2003-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0115847A (pt) | Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos | |
| BR0309544A (pt) | Preparação farmacêutica contendo oxicodona e naloxona | |
| WO2001039777A8 (en) | Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof | |
| AR023715A1 (es) | Composicion farmaceutica para un sujeto que necesita una elevacion del contenido de nad intracelular, y el uso de la misma para la manufactura de unmedicamento para aumentar las respuestas celulares protectoras al stress genotoxico en la piel | |
| BR0213358A (pt) | Uso de flibanserina | |
| BR0112476A (pt) | Uso de agonistas do receptor d2/d3 de dopamina para tratar fibromialgia | |
| BR9910035A (pt) | Derivados de guanidina | |
| BR0011856A (pt) | Agonistas de receptor a2a de n-pirazol | |
| BR0309855A (pt) | Pirazolpiridinas substituìdas com carbamato | |
| BR0111908A (pt) | Composto, composição farmacêutica, uso do composto, e, método para o tratamento e/ou prevenção de distúrbios ou doenças | |
| BR9913932A (pt) | Uso de análogos de glp-1 no tratamento de derrame | |
| BR0108977A (pt) | Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina | |
| BR0015974A (pt) | Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto | |
| BR0016801A (pt) | Preparação antidiabética para administração oral | |
| BR0011854A (pt) | Agonistas de receptores de a2a de c-pirazola | |
| FI920026A0 (fi) | Farmaceutisk komposition anvaendbar som avmagringsmedicin. | |
| ES2166111T3 (es) | Uso de tiagabina para el tratamiento de trastornos del sueño. | |
| BR0115109A (pt) | Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese | |
| BRPI0007487B8 (pt) | difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase | |
| BR0014525A (pt) | Processo de tratamento de distúrbios metabólicos, especialmente diabetes, ou uma doença ou condição associada com diabetes | |
| AR052921A1 (es) | Uso de ranolazina para la preparacion de una composicion farmaceutica y composicion farmaceutica | |
| AR015493A1 (es) | DERIVADOS CICLOHEXILOS , COMPOSICIONES FARMACÉUTICAS Y EL USO DE LOS MISMOS PARA LA MANUFACTURA DE UNA COMPOSICIoN uTIL PARA INHIBIR LA ACTIVIDAD IN VITRO DE NEURAMINIDASA Y PARA EL TRATAMIENTO O PROFILAXIS DE LA INFECCIoN DE INFLUENZA Y PARA TRATAIMIENTO, Y UN MÉTODO IN VITRO PARA INHIBIR LA ACTIVI | |
| BR0111913A (pt) | Análogos de gabapentina para distúrbios do sono | |
| BR0011850A (pt) | Agonistas de receptor a2a de propargil fenil éter | |
| BR9810773A (pt) | Uso de um ingrediente anestésico local de ação prolongada, composição farmacêutica, uso de um anestésico local, e, kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |